Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-09-27 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
2023年股权激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of a 2023 equity incentive plan (股权激励计划) by Beijing Xinghao Pharmaceutical Co., Ltd. It includes extensive information about the plan's purpose, legal basis, management, scope, stock option and restricted stock details, pricing, performance conditions, and governance. The document is lengthy (15,000 characters) and contains substantive content about the equity incentive plan itself, not just an announcement or summary. It is not a financial report like an annual or interim report, nor is it a call transcript or legal proceeding. It is a regulatory announcement related to capital structure and financing activities, specifically about stock options and restricted stock grants to management and employees. This fits best under the category of Capital/Financing Update (CAP), as it details changes and plans regarding the company's capital structure through equity incentives. Therefore, the filing type is CAP with high confidence.
2023-09-27 Chinese
关于独立董事公开征集表决权公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a public announcement by an independent director soliciting voting rights from shareholders for an upcoming extraordinary general meeting (the 2023 fifth extraordinary shareholders meeting) scheduled for October 16, 2023. It details the agenda items related to a 2023 equity incentive plan and the procedures for shareholders to authorize voting rights to the independent director. The document is not a report of voting results, nor is it a proxy solicitation statement or a management report. It is a solicitation announcement for voting rights ahead of a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) as it relates to official shareholder voting matters. However, since it is a solicitation of voting rights rather than the announcement of voting results, it is best classified under DVA as it concerns voting rights announcements. The document length is under 5,000 characters, but it is substantive and not merely a report publication announcement. Therefore, the best fit is DVA.
2023-09-27 Chinese
关于召开2023年第五次临时股东大会通知公告（提供网络投票）
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a notice announcing the convening of the 2023 fifth extraordinary general meeting of shareholders (临时股东大会) for Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed, and procedural information for shareholders. The document does not contain financial statements or results but serves as an official announcement for the meeting and voting process. The document length is 3147 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself and voting arrangements rather than solicitation materials or voting results, the best fit is Declaration of Voting Results & Voting Rights Announcements (DVA) as it relates to shareholder voting rights and meeting announcements.
2023-09-27 Chinese
监事会关于2023年股权激励计划（草案）的核查意见
Board/Management Information Classification · 95% confidence The document is a supervisory board's verification opinion on the company's 2023 equity incentive plan draft. It references compliance with various laws and regulations, confirms the legitimacy of the incentive plan, and states that the plan will be submitted to the shareholders' meeting for approval. The document is an official announcement related to corporate governance and equity incentive plans, but it is not a full report like an annual or interim report, nor is it a financial statement or earnings release. It is also not a proxy solicitation or voting result announcement. The content fits best under Board/Management Information (MANG) as it relates to management decisions and governance matters regarding equity incentives.
2023-09-27 Chinese
第七届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the seventh Supervisory Board of Beijing Xinghao Pharmaceutical Co., Ltd. It details meeting attendance, agenda items, voting results, and references to related disclosures on the stock exchange platform. The content focuses on internal governance matters such as approval of a 2023 equity incentive plan and nomination of core employees, with no financial statements or detailed financial data presented. The document is relatively short (2460 characters) and serves as a meeting resolution announcement rather than a full report or detailed management discussion. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results declaration but rather a board/management information announcement about supervisory board meeting decisions. Therefore, the best fitting category is Board/Management Information (MANG).
2023-09-27 Chinese
第六届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to further disclosures on the stock exchange platform. The content focuses on board decisions regarding a 2023 equity incentive plan, core employee nominations, and authorization for the board to handle related matters. There is no financial data or comprehensive report content, but rather a formal announcement of board meeting resolutions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length (4663 characters) and detailed meeting minutes support this classification rather than a brief announcement or a full report.
2023-09-27 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.